Wave Life Sciences (WVE) Price Target Raised to $65.00 at Mizuho

Wave Life Sciences (NASDAQ:WVE) had its price target upped by analysts at Mizuho from $34.00 to $65.00 in a research report issued on Monday. The brokerage currently has a “buy” rating on the stock. Mizuho’s price target indicates a potential upside of 56.63% from the company’s current price.

Several other research firms also recently commented on WVE. BidaskClub upgraded shares of Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 21st. Leerink Swann upped their price objective on shares of Wave Life Sciences from $53.00 to $64.00 and gave the company an “outperform” rating in a report on Wednesday, February 21st. SunTrust Banks upped their price objective on shares of Wave Life Sciences to $60.00 and gave the company a “buy” rating in a report on Friday, March 9th. Zacks Investment Research downgraded shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 13th. Finally, TheStreet upgraded shares of Wave Life Sciences from a “d+” rating to a “c-” rating in a research note on Friday, January 5th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. Wave Life Sciences has a consensus rating of “Buy” and an average target price of $53.40.

How to Become a New Pot Stock Millionaire

Wave Life Sciences stock opened at $41.50 on Monday. Wave Life Sciences has a fifty-two week low of $15.15 and a fifty-two week high of $55.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.67 and a current ratio of 7.67.

In related news, insider Chris Francis sold 21,639 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $55.40, for a total value of $1,198,800.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Chandra Vargeese sold 2,000 shares of the company’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $40.00, for a total transaction of $80,000.00. The disclosure for this sale can be found here. Insiders sold 24,466 shares of company stock worth $1,321,808 over the last 90 days. 53.00% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. Bridger Management LLC grew its stake in Wave Life Sciences by 16.2% during the fourth quarter. Bridger Management LLC now owns 337,949 shares of the company’s stock worth $11,862,000 after buying an additional 47,064 shares in the last quarter. Perceptive Advisors LLC grew its stake in Wave Life Sciences by 3.1% during the fourth quarter. Perceptive Advisors LLC now owns 662,798 shares of the company’s stock worth $23,264,000 after buying an additional 20,000 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Wave Life Sciences during the fourth quarter worth about $828,000. Goldman Sachs Group Inc. acquired a new stake in Wave Life Sciences during the fourth quarter worth about $222,000. Finally, Spark Investment Management LLC acquired a new stake in Wave Life Sciences during the fourth quarter worth about $1,411,000. Hedge funds and other institutional investors own 79.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3277307/wave-life-sciences-wve-price-target-raised-to-65-00-at-mizuho.html.

About Wave Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Analyst Recommendations for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Smart Sand  Expected to Post Earnings of $0.08 Per Share
Smart Sand Expected to Post Earnings of $0.08 Per Share
JetPay  Getting Favorable News Coverage, Accern Reports
JetPay Getting Favorable News Coverage, Accern Reports
Glen Burnie Bancorp  Receives News Sentiment Rating of -0.08
Glen Burnie Bancorp Receives News Sentiment Rating of -0.08
MKS Instruments  Releases Q2 Earnings Guidance
MKS Instruments Releases Q2 Earnings Guidance
Vipshop  versus Qurate Retail Group  Critical Contrast
Vipshop versus Qurate Retail Group Critical Contrast
Reviewing Chunghwa Telecom  and Cellcom
Reviewing Chunghwa Telecom and Cellcom


© 2006-2018 Ticker Report. Google+.